Cumberland Pharmaceuticals Inc. (CPIX) 10-Year Financial Performance & Capital Metrics

CPIX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsHospital Acute Care

AboutCumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Show more

Revenue $38M -4.3%
EBITDA -$389K +73.2%
Net Income -$6M -3.2%
EPS (Diluted) -0.46 -4.5%
Gross Margin 82.61% -2.4%
EBITDA Margin -1.03% +72.0%
Operating Margin -16.99% +29.7%
Net Margin -17.11% -7.8%
ROE -25.02% -29.9%
ROIC -17.7% +17.8%
Debt/Equity 0.91 +44.9%
Interest Coverage -10.62 +25.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.26%

5Y1.95%

3Y1.71%

TTM12.21%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM69.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM68.83%

ROCE

10Y Avg-8.68%

5Y Avg-11.58%

3Y Avg-12.71%

Latest-13.16%

Peer Comparison

Hospital Acute Care

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CPIXCumberland Pharmaceuticals Inc.	71.19M	4.76	-10.35	-4.26%	-8.06%	-12.9%		0.91

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	33.52M	33.03M	41.15M	40.74M	34.39M	37.44M	35.99M	42.01M	39.55M	37.87M
Revenue Growth %	-0.09%	-0.01%	0.25%	-0.01%	-0.16%	0.09%	-0.04%	0.17%	-0.06%	-0.04%
Cost of Goods Sold+	4.97M	5.96M	7.37M	7.38M	7.42M	8.65M	8.81M	9.12M	6.07M	6.59M
COGS % of Revenue	0.15%	0.18%	0.18%	0.18%	0.22%	0.23%	0.24%	0.22%	0.15%	0.17%
Gross Profit+	28.55M	27.07M	33.78M	33.36M	26.97M	28.79M	27.17M	32.89M	33.49M	31.28M
Gross Margin %	0.85%	0.82%	0.82%	0.82%	0.78%	0.77%	0.76%	0.78%	0.85%	0.83%
Gross Profit Growth %	-0.1%	-0.05%	0.25%	-0.01%	-0.19%	0.07%	-0.06%	0.21%	0.02%	-0.07%
Operating Expenses+	27.44M	28.5M	37.86M	40.75M	36.26M	35.17M	34.85M	38.6M	43.04M	37.71M
OpEx % of Revenue	0.82%	0.86%	0.92%	1%	1.05%	0.94%	0.97%	0.92%	1.09%	1%
Selling, General & Admin	21.6M	23.12M	31.52M	30.66M	25.25M	24.96M	24.8M	26.84M	29.1M	28.15M
SG&A % of Revenue	0.64%	0.7%	0.77%	0.75%	0.73%	0.67%	0.69%	0.64%	0.74%	0.74%
Research & Development	3.85M	3.19M	3.9M	7.32M	6.87M	5.77M	5.68M	6.69M	5.83M	4.82M
R&D % of Revenue	0.11%	0.1%	0.09%	0.18%	0.2%	0.15%	0.16%	0.16%	0.15%	0.13%
Other Operating Expenses	1.99M	2.19M	2.44M	2.77M	4.13M	4.43M	4.37M	5.07M	8.1M	4.75M
Operating Income+	-1.11M	-1.43M	-4.08M	-7.39M	-9.29M	-6.38M	-7.68M	-5.7M	-9.55M	-6.43M
Operating Margin %	-0.03%	-0.04%	-0.1%	-0.18%	-0.27%	-0.17%	-0.21%	-0.14%	-0.24%	-0.17%
Operating Income Growth %	-1.31%	-0.29%	-1.85%	-0.81%	-0.26%	0.31%	-0.2%	0.26%	-0.67%	0.33%
EBITDA+	1.14M	963.78K	-1.43M	-4.41M	-4.88M	-1.63M	-3.07M	-376.82K	-1.45M	-389.11K
EBITDA Margin %	0.03%	0.03%	-0.03%	-0.11%	-0.14%	-0.04%	-0.09%	-0.01%	-0.04%	-0.01%
EBITDA Growth %	-0.8%	-0.15%	-2.49%	-2.07%	-0.11%	0.67%	-0.88%	0.88%	-2.85%	0.73%
D&A (Non-Cash Add-back)	2.25M	2.4M	2.65M	2.98M	4.4M	4.75M	4.61M	5.33M	8.1M	6.04M
EBIT	1.32M	-1.23M	-3.78M	-10.61M	-9.04M	-6.31M	-5.46M	-5M	-5.62M	-5.86M
Net Interest Income+	135.33K	98.27K	206.42K	368.64K	-2.82K	-188.28K	-71.95K	-487.59K	-381.01K	-271.06K
Interest Income	209.18K	204.66K	299.33K	564.48K	243.36K	75.34K	26.08K	98.41K	286.85K	334.44K
Interest Expense	73.86K	106.39K	92.9K	195.85K	246.19K	263.63K	98.03K	586K	667.86K	605.51K
Other Income/Expense	135.33K	98.27K	206.42K	368.64K	-2.82K	-188.28K	2.12M	123.74K	3.27M	-33.98K
Pretax Income+	1.25M	-1.33M	-3.87M	-7.02M	-9.29M	-6.57M	-5.56M	-5.58M	-6.28M	-6.47M
Pretax Margin %	0.04%	-0.04%	-0.09%	-0.17%	-0.27%	-0.18%	-0.15%	-0.13%	-0.16%	-0.17%
Income Tax+	575.83K	-330.92K	4.17M	16.64K	-79.32K	55.9K	34.89K	68.85K	45.77K	-22.67K
Effective Tax Rate %	0.59%	0.71%	2.06%	0.99%	0.38%	0.51%	0.63%	1%	1%	1%
Net Income+	731.35K	-944.68K	-7.98M	-6.96M	-3.54M	-3.34M	-3.51M	-5.57M	-6.28M	-6.48M
Net Margin %	0.02%	-0.03%	-0.19%	-0.17%	-0.1%	-0.09%	-0.1%	-0.13%	-0.16%	-0.17%
Net Income Growth %	-0.7%	-2.29%	-7.45%	0.13%	0.49%	0.06%	-0.05%	-0.59%	-0.13%	-0.03%
Net Income (Continuing)	671.11K	-1M	-8.05M	-10.82M	-9.21M	-6.63M	-5.6M	-5.65M	-6.33M	-6.44M
Discontinued Operations	0	0	0	0	5.67M	3.21M	1.99M	0	0	0
Minority Interest	-68.13K	-127.38K	-198.56K	-274.27K	-37.62K	-117.12K	-212.33K	-292.13K	-343.57K	-307.52K
EPS (Diluted)+	0.04	-0.06	-0.50	-0.45	-0.23	-0.22	-0.24	-0.38	-0.44	-0.46
EPS Growth %	-0.71%	-2.46%	-7.59%	0.1%	0.49%	0.04%	-0.09%	-0.58%	-0.16%	-0.05%
EPS (Basic)	0.04	-0.06	-0.50	-0.45	-0.23	-0.22	-0.24	-0.38	-0.44	-0.46
Diluted Shares Outstanding	17.09M	16.24M	15.91M	15.61M	15.4M	15.16M	14.9M	14.56M	14.3M	14.06M
Basic Shares Outstanding	16.72M	15.74M	15.91M	15.57M	15.4M	15.16M	14.9M	14.56M	14.3M	14.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	67.11M	65.55M	68.68M	74.87M	50.16M	49.97M	45.69M	45.87M	35.71M	36.45M
Cash & Short-Term Investments	52.77M	50.13M	50.09M	36.23M	28.21M	24.75M	27.04M	19.76M	18.32M	17.96M
Cash Only	38.2M	34.51M	45.41M	27.94M	28.21M	24.75M	27.04M	19.76M	18.32M	17.96M
Short-Term Investments	14.56M	15.62M	4.67M	8.29M	0	0	0	0	0	0
Accounts Receivable	6.08M	7.33M	8.4M	7.84M	7.86M	12.38M	6.88M	13.16M	9.76M	11.7M
Days Sales Outstanding	66.18	81.01	74.46	70.28	83.42	120.67	69.76	114.37	90.05	112.79
Inventory	4.27M	5.37M	6.74M	27.83M	8.87M	10.64M	8.43M	9.86M	4.61M	4M
Days Inventory Outstanding	313.72	329.05	333.67	1.38K	436.31	448.74	349.2	394.82	277.32	221.68
Other Current Assets	2.53M	0	0	0	2.46M	0	0	3.08M	3.03M	2.79M
Total Non-Current Assets+	24.81M	27.86M	24.55M	37.83M	54.39M	46.49M	38.77M	47.05M	46.06M	39.13M
Property, Plant & Equipment	536.45K	464.45K	528.88K	771.21K	3.71M	2.6M	1.47M	5.5M	7.04M	6.45M
Fixed Asset Turnover	62.48x	71.11x	77.81x	52.83x	9.27x	14.39x	24.53x	7.63x	5.62x	5.87x
Goodwill	0	0	0	784K	882K	882K	882K	914K	914K	914K
Intangible Assets	21.17M	22.15M	21.44M	33.66M	30.92M	28.12M	23.95M	30.59M	22.61M	17.97M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.89M	2.12M	2.49M	2.53M	18.85M	14.89M	12.47M	10.05M	15.5M	13.79M
Total Assets+	91.92M	93.4M	93.23M	112.69M	104.55M	96.46M	84.46M	92.93M	81.78M	75.58M
Asset Turnover	0.36x	0.35x	0.44x	0.36x	0.33x	0.39x	0.43x	0.45x	0.48x	0.50x
Asset Growth %	-0.04%	0.02%	-0%	0.21%	-0.07%	-0.08%	-0.12%	0.1%	-0.12%	-0.08%
Total Current Liabilities+	12.41M	14.79M	17.69M	27.8M	24.15M	25.67M	19.28M	28.58M	27.98M	31.62M
Accounts Payable	2.88M	8.04M	8.98M	11.09M	9.99M	13.4M	9.64M	10.82M	14.04M	13.91M
Days Payables Outstanding	211.4	492.29	444.7	548.79	491.51	565.08	399.37	433.07	844.58	771.14
Short-Term Debt	0	0	0	0	0	2.19M	0	0	0	5.1M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	9.53M	5.45M	6.33M	15.45M	9.03M	5.99M	5.96M	13.57M	10.79M	10.18M
Current Ratio	5.41x	4.43x	3.88x	2.69x	2.08x	1.95x	2.37x	1.60x	1.28x	1.15x
Quick Ratio	5.06x	4.07x	3.50x	1.69x	1.71x	1.53x	1.93x	1.26x	1.11x	1.03x
Cash Conversion Cycle	168.49	-82.23	-36.57	898.12	28.22	4.32	19.59	76.12	-477.2	-436.67
Total Non-Current Liabilities+	2.69M	5.49M	11.62M	29.32M	29.31M	23.92M	22.58M	28.37M	24.53M	21.42M
Long-Term Debt	1.7M	4.1M	9.8M	20M	18.5M	15M	15M	16.2M	12.78M	10.18M
Capital Lease Obligations	0	0	0	0	2.08M	1.06M	90.02K	4.59M	5.3M	4.94M
Deferred Tax Liabilities	0	3.24M	2.07M	1.97M	0	0	0	0	0	0
Other Non-Current Liabilities	987.43K	1.39M	1.82M	9.32M	8.74M	7.86M	7.49M	7.59M	6.45M	6.3M
Total Liabilities	15.1M	20.28M	29.31M	57.12M	53.46M	49.59M	41.86M	56.95M	52.52M	53.04M
Total Debt+	1.7M	4.1M	9.8M	20M	21.5M	19.26M	16.06M	20.96M	18.43M	20.57M
Net Debt	-36.5M	-30.41M	-35.61M	-7.94M	-6.72M	-5.49M	-10.98M	1.2M	106.86K	2.61M
Debt / Equity	0.02x	0.06x	0.15x	0.36x	0.42x	0.41x	0.38x	0.58x	0.63x	0.91x
Debt / EBITDA	1.50x	4.25x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-32.16x	-31.55x	-	-	-	-	-	-	-	-
Interest Coverage	-15.05x	-13.47x	-43.93x	-37.74x	-37.73x	-24.21x	-78.32x	-9.74x	-14.31x	-10.62x
Total Equity+	76.82M	73.12M	63.92M	55.57M	51.09M	46.87M	42.6M	35.97M	29.26M	22.55M
Equity Growth %	-0.05%	-0.05%	-0.13%	-0.13%	-0.08%	-0.08%	-0.09%	-0.16%	-0.19%	-0.23%
Book Value per Share	4.49	4.50	4.02	3.56	3.32	3.09	2.86	2.47	2.05	1.60
Total Shareholders' Equity	76.89M	73.25M	64.12M	55.84M	51.12M	46.99M	42.81M	36.27M	29.6M	22.85M
Common Stock	57.34M	54.64M	52.41M	51.1M	49.91M	49.12M	48.45M	47.47M	47.09M	46.82M
Retained Earnings	19.55M	18.6M	11.71M	4.75M	1.21M	-2.13M	-5.64M	-11.21M	-17.49M	-23.97M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	-68.13K	-127.38K	-198.56K	-274.27K	-37.62K	-117.12K	-212.33K	-292.13K	-343.57K	-307.52K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	5.88M	569.48K	-557.71K	3.11M	3.06M	5.42M	6.34M	8.45M	6.09M	-612.19K
Operating CF Margin %	0.18%	0.02%	-0.01%	0.08%	0.09%	0.14%	0.18%	0.2%	0.15%	-0.02%
Operating CF Growth %	-0.12%	-0.9%	-1.98%	6.58%	-0.02%	0.77%	0.17%	0.33%	-0.28%	-1.1%
Net Income	671.11K	-1M	-8.05M	-7.04M	-3.54M	-3.42M	-3.6M	-5.65M	-6.28M	-6.48M
Depreciation & Amortization	2.25M	2.4M	2.65M	2.98M	4.4M	4.75M	4.61M	5.33M	5.77M	6.04M
Stock-Based Compensation	622.5K	852.1K	1.49M	1.36M	1.49M	1.05M	741.87K	447.5K	365.04K	301.89K
Deferred Taxes	490.23K	619.58K	4.21M	81.89K	0	21.8K	-192.82K	0	0	0
Other Non-Cash Items	-121.72K	1.04M	-65.21K	-150.44K	2.34M	-515.72K	-3.39M	-2.64M	1.6M	-1.77M
Working Capital Changes	1.97M	-3.33M	-784.76K	5.87M	-1.64M	3.53M	8.18M	10.97M	4.63M	1.29M
Change in Receivables	-572.39K	-1.25M	-1.06M	550.86K	-1.4M	-4.52M	5.5M	-6.12M	3.4M	-1.94M
Change in Inventory	1.33M	-1.1M	-1.37M	460.5K	1.11M	2.13M	4.82M	1.38M	-23.14K	2.41M
Change in Payables	1.48M	191.9K	2.31M	4.31M	0	6.57M	-757.59K	15.07M	3.72M	-991.36K
Cash from Investing+	-2.34M	-3.12M	9.51M	-27.72M	2.3M	-1.76M	-501.89K	-13.67M	-105.69K	57.84K
Capital Expenditures	-2.7M	-2.13M	-1.49M	-4.28M	-246.2K	-2.11M	-354.46K	-2.07M	-453.05K	-179.71K
CapEx % of Revenue	0.08%	0.06%	0.04%	0.1%	0.01%	0.06%	0.01%	0.05%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.56M	-2M	-1.21M	-7.27M	7.54M	356.14K	52.57K	1.9M	347.36K	237.56K
Cash from Financing+	-5.19M	-1.15M	1.95M	7.14M	-5.08M	-7.12M	-3.55M	-2.06M	-7.42M	196.9K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.56M	-1.03M	-27.95K	-383.31K	-85.61K	-1.76M	-2.17M	-2.21M	-3.27M	-1.72M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	3.18M	-1.56M	-2.05M	-1.16M	2.81M	3.3M	5.99M	6.38M	5.64M	-791.9K
FCF Margin %	0.09%	-0.05%	-0.05%	-0.03%	0.08%	0.09%	0.17%	0.15%	0.14%	-0.02%
FCF Growth %	-0.07%	-1.49%	-0.31%	0.43%	3.42%	0.17%	0.81%	0.07%	-0.12%	-1.14%
FCF per Share	0.19	-0.10	-0.13	-0.07	0.18	0.22	0.40	0.44	0.39	-0.06
FCF Conversion (FCF/Net Income)	8.04x	-0.60x	0.07x	-0.45x	-0.86x	-1.62x	-1.81x	-1.52x	-0.97x	0.09x
Interest Paid	-27.43K	21.85K	14.99K	95.97K	0	0	0	523.16K	647.14K	0
Taxes Paid	-52.24K	8.36K	18K	15.44K	0	0	0	3.3K	108.82K	15K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	0.93%	-1.26%	-11.64%	-11.65%	-6.63%	-6.82%	-7.84%	-14.18%	-19.25%	-25.02%
Return on Invested Capital (ROIC)	-2.05%	-2.59%	-8.62%	-14.6%	-15.14%	-11.16%	-15.77%	-12.44%	-21.54%	-17.7%
Gross Margin	85.18%	81.96%	82.09%	81.89%	78.42%	76.89%	75.51%	78.29%	84.66%	82.61%
Net Margin	2.18%	-2.86%	-19.39%	-17.09%	-10.29%	-8.92%	-9.75%	-13.26%	-15.88%	-17.11%
Debt / Equity	0.02x	0.06x	0.15x	0.36x	0.42x	0.41x	0.38x	0.58x	0.63x	0.91x
Interest Coverage	-15.05x	-13.47x	-43.93x	-37.74x	-37.73x	-24.21x	-78.32x	-9.74x	-14.31x	-10.62x
FCF Conversion	8.04x	-0.60x	0.07x	-0.45x	-0.86x	-1.62x	-1.81x	-1.52x	-0.97x	0.09x
Revenue Growth	-9.17%	-1.47%	24.6%	-0.99%	-15.59%	8.88%	-3.89%	16.75%	-5.85%	-4.26%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	37.51M	36.54M
Product Growth	-	-	-	-	-	-	-	-	-	-2.60%
Manufactured Product, Other	-	-	-	-	-	-	-	-	2.04M	1.33M
Manufactured Product, Other Growth	-	-	-	-	-	-	-	-	-	-34.76%
Kristalose	-	-	11.46M	12.06M	12.9M	15.57M	15.99M	15.21M	-	-
Kristalose Growth	-	-	-	5.24%	6.96%	20.72%	2.74%	-4.93%	-	-
Sancuso	-	-	-	-	-	-	-	13.21M	-	-
Sancuso Growth	-	-	-	-	-	-	-	-	-	-
Product, Vibativ	-	-	-	5.08M	8.69M	10.87M	11.7M	7.49M	-	-
Product, Vibativ Growth	-	-	-	-	71.26%	25.08%	7.66%	-36.03%	-	-
Caldolor	-	-	4.18M	5M	5.22M	5.34M	4.97M	4.83M	-	-
Caldolor Growth	-	-	-	19.71%	4.40%	2.20%	-6.87%	-2.88%	-	-
Acetadote	-	-	6.58M	4.28M	3.82M	1.87M	850.99K	501.04K	-	-
Acetadote Growth	-	-	-	-34.86%	-10.73%	-50.99%	-54.59%	-41.12%	-	-
RediTrex	-	-	-	-	-	856.66K	55.32K	-126.73K	-	-
RediTrex Growth	-	-	-	-	-	-	-93.54%	-329.07%	-	-
Vaprisol	-	-	1.58M	1.76M	936.62K	1.08M	1.86M	-447.7K	-	-
Vaprisol Growth	-	-	-	11.91%	-46.90%	15.01%	72.63%	-124.08%	-	-
Omeclamox-Pak	-	-	1.76M	623.3K	837.83K	257.09K	-388.66K	-	-	-
Omeclamox-Pak Growth	-	-	-	-64.62%	34.42%	-69.31%	-251.18%	-	-	-
Product, Ethyol	-	838.39K	10.84M	10.5M	12.77M	-	-	-	-	-
Product, Ethyol Growth	-	-	1192.37%	-3.09%	21.67%	-	-	-	-	-
Product, Totect	-	-	3.99M	900K	369.91K	-	-	-	-	-
Product, Totect Growth	-	-	-	-77.46%	-58.90%	-	-	-	-	-
Product, Acetadote, Generic	4.5M	4.8M	-	-	-	-	-	-	-	-
Product, Acetadote, Generic Growth	-	6.67%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Non-US	-	-	-	2.1M	1.5M	2.4M	2.2M	1.5M	1.1M	2.7M
Non-US Growth	-	-	-	-	-28.57%	60.00%	-8.33%	-31.82%	-26.67%	145.45%
Outside United States	800K	2M	-	-	-	-	-	-	-	-
Outside United States Growth	-	150.00%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cumberland Pharmaceuticals Inc. (CPIX) reported $41.3M in revenue for fiscal year 2024. This represents a 19% decrease from $51.1M in 2011.

Cumberland Pharmaceuticals Inc. (CPIX) saw revenue decline by 4.3% over the past year.

Cumberland Pharmaceuticals Inc. (CPIX) reported a net loss of $3.3M for fiscal year 2024.

Dividend & Returns

Cumberland Pharmaceuticals Inc. (CPIX) has a return on equity (ROE) of -25.0%. Negative ROE indicates the company is unprofitable.

Cumberland Pharmaceuticals Inc. (CPIX) generated $6.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Cumberland Pharmaceuticals Inc. (CPIX) 10-Year Financial Performance & Capital Metrics

CPIX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsHospital Acute Care

Revenue $38M -4.3%
EBITDA -$389K +73.2%
Net Income -$6M -3.2%
EPS (Diluted) -0.46 -4.5%
Gross Margin 82.61% -2.4%
EBITDA Margin -1.03% +72.0%
Operating Margin -16.99% +29.7%
Net Margin -17.11% -7.8%
ROE -25.02% -29.9%
ROIC -17.7% +17.8%
Debt/Equity 0.91 +44.9%
Interest Coverage -10.62 +25.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.26%

5Y1.95%

3Y1.71%

TTM12.21%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM69.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM68.83%

ROCE

10Y Avg-8.68%

5Y Avg-11.58%

3Y Avg-12.71%

Latest-13.16%

Peer Comparison

Hospital Acute Care

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CPIXCumberland Pharmaceuticals Inc.	71.19M	4.76	-10.35	-4.26%	-8.06%	-12.9%		0.91

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	33.52M	33.03M	41.15M	40.74M	34.39M	37.44M	35.99M	42.01M	39.55M	37.87M
Revenue Growth %	-0.09%	-0.01%	0.25%	-0.01%	-0.16%	0.09%	-0.04%	0.17%	-0.06%	-0.04%
Cost of Goods Sold+	4.97M	5.96M	7.37M	7.38M	7.42M	8.65M	8.81M	9.12M	6.07M	6.59M
COGS % of Revenue	0.15%	0.18%	0.18%	0.18%	0.22%	0.23%	0.24%	0.22%	0.15%	0.17%
Gross Profit+	28.55M	27.07M	33.78M	33.36M	26.97M	28.79M	27.17M	32.89M	33.49M	31.28M
Gross Margin %	0.85%	0.82%	0.82%	0.82%	0.78%	0.77%	0.76%	0.78%	0.85%	0.83%
Gross Profit Growth %	-0.1%	-0.05%	0.25%	-0.01%	-0.19%	0.07%	-0.06%	0.21%	0.02%	-0.07%
Operating Expenses+	27.44M	28.5M	37.86M	40.75M	36.26M	35.17M	34.85M	38.6M	43.04M	37.71M
OpEx % of Revenue	0.82%	0.86%	0.92%	1%	1.05%	0.94%	0.97%	0.92%	1.09%	1%
Selling, General & Admin	21.6M	23.12M	31.52M	30.66M	25.25M	24.96M	24.8M	26.84M	29.1M	28.15M
SG&A % of Revenue	0.64%	0.7%	0.77%	0.75%	0.73%	0.67%	0.69%	0.64%	0.74%	0.74%
Research & Development	3.85M	3.19M	3.9M	7.32M	6.87M	5.77M	5.68M	6.69M	5.83M	4.82M
R&D % of Revenue	0.11%	0.1%	0.09%	0.18%	0.2%	0.15%	0.16%	0.16%	0.15%	0.13%
Other Operating Expenses	1.99M	2.19M	2.44M	2.77M	4.13M	4.43M	4.37M	5.07M	8.1M	4.75M
Operating Income+	-1.11M	-1.43M	-4.08M	-7.39M	-9.29M	-6.38M	-7.68M	-5.7M	-9.55M	-6.43M
Operating Margin %	-0.03%	-0.04%	-0.1%	-0.18%	-0.27%	-0.17%	-0.21%	-0.14%	-0.24%	-0.17%
Operating Income Growth %	-1.31%	-0.29%	-1.85%	-0.81%	-0.26%	0.31%	-0.2%	0.26%	-0.67%	0.33%
EBITDA+	1.14M	963.78K	-1.43M	-4.41M	-4.88M	-1.63M	-3.07M	-376.82K	-1.45M	-389.11K
EBITDA Margin %	0.03%	0.03%	-0.03%	-0.11%	-0.14%	-0.04%	-0.09%	-0.01%	-0.04%	-0.01%
EBITDA Growth %	-0.8%	-0.15%	-2.49%	-2.07%	-0.11%	0.67%	-0.88%	0.88%	-2.85%	0.73%
D&A (Non-Cash Add-back)	2.25M	2.4M	2.65M	2.98M	4.4M	4.75M	4.61M	5.33M	8.1M	6.04M
EBIT	1.32M	-1.23M	-3.78M	-10.61M	-9.04M	-6.31M	-5.46M	-5M	-5.62M	-5.86M
Net Interest Income+	135.33K	98.27K	206.42K	368.64K	-2.82K	-188.28K	-71.95K	-487.59K	-381.01K	-271.06K
Interest Income	209.18K	204.66K	299.33K	564.48K	243.36K	75.34K	26.08K	98.41K	286.85K	334.44K
Interest Expense	73.86K	106.39K	92.9K	195.85K	246.19K	263.63K	98.03K	586K	667.86K	605.51K
Other Income/Expense	135.33K	98.27K	206.42K	368.64K	-2.82K	-188.28K	2.12M	123.74K	3.27M	-33.98K
Pretax Income+	1.25M	-1.33M	-3.87M	-7.02M	-9.29M	-6.57M	-5.56M	-5.58M	-6.28M	-6.47M
Pretax Margin %	0.04%	-0.04%	-0.09%	-0.17%	-0.27%	-0.18%	-0.15%	-0.13%	-0.16%	-0.17%
Income Tax+	575.83K	-330.92K	4.17M	16.64K	-79.32K	55.9K	34.89K	68.85K	45.77K	-22.67K
Effective Tax Rate %	0.59%	0.71%	2.06%	0.99%	0.38%	0.51%	0.63%	1%	1%	1%
Net Income+	731.35K	-944.68K	-7.98M	-6.96M	-3.54M	-3.34M	-3.51M	-5.57M	-6.28M	-6.48M
Net Margin %	0.02%	-0.03%	-0.19%	-0.17%	-0.1%	-0.09%	-0.1%	-0.13%	-0.16%	-0.17%
Net Income Growth %	-0.7%	-2.29%	-7.45%	0.13%	0.49%	0.06%	-0.05%	-0.59%	-0.13%	-0.03%
Net Income (Continuing)	671.11K	-1M	-8.05M	-10.82M	-9.21M	-6.63M	-5.6M	-5.65M	-6.33M	-6.44M
Discontinued Operations	0	0	0	0	5.67M	3.21M	1.99M	0	0	0
Minority Interest	-68.13K	-127.38K	-198.56K	-274.27K	-37.62K	-117.12K	-212.33K	-292.13K	-343.57K	-307.52K
EPS (Diluted)+	0.04	-0.06	-0.50	-0.45	-0.23	-0.22	-0.24	-0.38	-0.44	-0.46
EPS Growth %	-0.71%	-2.46%	-7.59%	0.1%	0.49%	0.04%	-0.09%	-0.58%	-0.16%	-0.05%
EPS (Basic)	0.04	-0.06	-0.50	-0.45	-0.23	-0.22	-0.24	-0.38	-0.44	-0.46
Diluted Shares Outstanding	17.09M	16.24M	15.91M	15.61M	15.4M	15.16M	14.9M	14.56M	14.3M	14.06M
Basic Shares Outstanding	16.72M	15.74M	15.91M	15.57M	15.4M	15.16M	14.9M	14.56M	14.3M	14.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	67.11M	65.55M	68.68M	74.87M	50.16M	49.97M	45.69M	45.87M	35.71M	36.45M
Cash & Short-Term Investments	52.77M	50.13M	50.09M	36.23M	28.21M	24.75M	27.04M	19.76M	18.32M	17.96M
Cash Only	38.2M	34.51M	45.41M	27.94M	28.21M	24.75M	27.04M	19.76M	18.32M	17.96M
Short-Term Investments	14.56M	15.62M	4.67M	8.29M	0	0	0	0	0	0
Accounts Receivable	6.08M	7.33M	8.4M	7.84M	7.86M	12.38M	6.88M	13.16M	9.76M	11.7M
Days Sales Outstanding	66.18	81.01	74.46	70.28	83.42	120.67	69.76	114.37	90.05	112.79
Inventory	4.27M	5.37M	6.74M	27.83M	8.87M	10.64M	8.43M	9.86M	4.61M	4M
Days Inventory Outstanding	313.72	329.05	333.67	1.38K	436.31	448.74	349.2	394.82	277.32	221.68
Other Current Assets	2.53M	0	0	0	2.46M	0	0	3.08M	3.03M	2.79M
Total Non-Current Assets+	24.81M	27.86M	24.55M	37.83M	54.39M	46.49M	38.77M	47.05M	46.06M	39.13M
Property, Plant & Equipment	536.45K	464.45K	528.88K	771.21K	3.71M	2.6M	1.47M	5.5M	7.04M	6.45M
Fixed Asset Turnover	62.48x	71.11x	77.81x	52.83x	9.27x	14.39x	24.53x	7.63x	5.62x	5.87x
Goodwill	0	0	0	784K	882K	882K	882K	914K	914K	914K
Intangible Assets	21.17M	22.15M	21.44M	33.66M	30.92M	28.12M	23.95M	30.59M	22.61M	17.97M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.89M	2.12M	2.49M	2.53M	18.85M	14.89M	12.47M	10.05M	15.5M	13.79M
Total Assets+	91.92M	93.4M	93.23M	112.69M	104.55M	96.46M	84.46M	92.93M	81.78M	75.58M
Asset Turnover	0.36x	0.35x	0.44x	0.36x	0.33x	0.39x	0.43x	0.45x	0.48x	0.50x
Asset Growth %	-0.04%	0.02%	-0%	0.21%	-0.07%	-0.08%	-0.12%	0.1%	-0.12%	-0.08%
Total Current Liabilities+	12.41M	14.79M	17.69M	27.8M	24.15M	25.67M	19.28M	28.58M	27.98M	31.62M
Accounts Payable	2.88M	8.04M	8.98M	11.09M	9.99M	13.4M	9.64M	10.82M	14.04M	13.91M
Days Payables Outstanding	211.4	492.29	444.7	548.79	491.51	565.08	399.37	433.07	844.58	771.14
Short-Term Debt	0	0	0	0	0	2.19M	0	0	0	5.1M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	9.53M	5.45M	6.33M	15.45M	9.03M	5.99M	5.96M	13.57M	10.79M	10.18M
Current Ratio	5.41x	4.43x	3.88x	2.69x	2.08x	1.95x	2.37x	1.60x	1.28x	1.15x
Quick Ratio	5.06x	4.07x	3.50x	1.69x	1.71x	1.53x	1.93x	1.26x	1.11x	1.03x
Cash Conversion Cycle	168.49	-82.23	-36.57	898.12	28.22	4.32	19.59	76.12	-477.2	-436.67
Total Non-Current Liabilities+	2.69M	5.49M	11.62M	29.32M	29.31M	23.92M	22.58M	28.37M	24.53M	21.42M
Long-Term Debt	1.7M	4.1M	9.8M	20M	18.5M	15M	15M	16.2M	12.78M	10.18M
Capital Lease Obligations	0	0	0	0	2.08M	1.06M	90.02K	4.59M	5.3M	4.94M
Deferred Tax Liabilities	0	3.24M	2.07M	1.97M	0	0	0	0	0	0
Other Non-Current Liabilities	987.43K	1.39M	1.82M	9.32M	8.74M	7.86M	7.49M	7.59M	6.45M	6.3M
Total Liabilities	15.1M	20.28M	29.31M	57.12M	53.46M	49.59M	41.86M	56.95M	52.52M	53.04M
Total Debt+	1.7M	4.1M	9.8M	20M	21.5M	19.26M	16.06M	20.96M	18.43M	20.57M
Net Debt	-36.5M	-30.41M	-35.61M	-7.94M	-6.72M	-5.49M	-10.98M	1.2M	106.86K	2.61M
Debt / Equity	0.02x	0.06x	0.15x	0.36x	0.42x	0.41x	0.38x	0.58x	0.63x	0.91x
Debt / EBITDA	1.50x	4.25x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-32.16x	-31.55x	-	-	-	-	-	-	-	-
Interest Coverage	-15.05x	-13.47x	-43.93x	-37.74x	-37.73x	-24.21x	-78.32x	-9.74x	-14.31x	-10.62x
Total Equity+	76.82M	73.12M	63.92M	55.57M	51.09M	46.87M	42.6M	35.97M	29.26M	22.55M
Equity Growth %	-0.05%	-0.05%	-0.13%	-0.13%	-0.08%	-0.08%	-0.09%	-0.16%	-0.19%	-0.23%
Book Value per Share	4.49	4.50	4.02	3.56	3.32	3.09	2.86	2.47	2.05	1.60
Total Shareholders' Equity	76.89M	73.25M	64.12M	55.84M	51.12M	46.99M	42.81M	36.27M	29.6M	22.85M
Common Stock	57.34M	54.64M	52.41M	51.1M	49.91M	49.12M	48.45M	47.47M	47.09M	46.82M
Retained Earnings	19.55M	18.6M	11.71M	4.75M	1.21M	-2.13M	-5.64M	-11.21M	-17.49M	-23.97M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	-68.13K	-127.38K	-198.56K	-274.27K	-37.62K	-117.12K	-212.33K	-292.13K	-343.57K	-307.52K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	5.88M	569.48K	-557.71K	3.11M	3.06M	5.42M	6.34M	8.45M	6.09M	-612.19K
Operating CF Margin %	0.18%	0.02%	-0.01%	0.08%	0.09%	0.14%	0.18%	0.2%	0.15%	-0.02%
Operating CF Growth %	-0.12%	-0.9%	-1.98%	6.58%	-0.02%	0.77%	0.17%	0.33%	-0.28%	-1.1%
Net Income	671.11K	-1M	-8.05M	-7.04M	-3.54M	-3.42M	-3.6M	-5.65M	-6.28M	-6.48M
Depreciation & Amortization	2.25M	2.4M	2.65M	2.98M	4.4M	4.75M	4.61M	5.33M	5.77M	6.04M
Stock-Based Compensation	622.5K	852.1K	1.49M	1.36M	1.49M	1.05M	741.87K	447.5K	365.04K	301.89K
Deferred Taxes	490.23K	619.58K	4.21M	81.89K	0	21.8K	-192.82K	0	0	0
Other Non-Cash Items	-121.72K	1.04M	-65.21K	-150.44K	2.34M	-515.72K	-3.39M	-2.64M	1.6M	-1.77M
Working Capital Changes	1.97M	-3.33M	-784.76K	5.87M	-1.64M	3.53M	8.18M	10.97M	4.63M	1.29M
Change in Receivables	-572.39K	-1.25M	-1.06M	550.86K	-1.4M	-4.52M	5.5M	-6.12M	3.4M	-1.94M
Change in Inventory	1.33M	-1.1M	-1.37M	460.5K	1.11M	2.13M	4.82M	1.38M	-23.14K	2.41M
Change in Payables	1.48M	191.9K	2.31M	4.31M	0	6.57M	-757.59K	15.07M	3.72M	-991.36K
Cash from Investing+	-2.34M	-3.12M	9.51M	-27.72M	2.3M	-1.76M	-501.89K	-13.67M	-105.69K	57.84K
Capital Expenditures	-2.7M	-2.13M	-1.49M	-4.28M	-246.2K	-2.11M	-354.46K	-2.07M	-453.05K	-179.71K
CapEx % of Revenue	0.08%	0.06%	0.04%	0.1%	0.01%	0.06%	0.01%	0.05%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.56M	-2M	-1.21M	-7.27M	7.54M	356.14K	52.57K	1.9M	347.36K	237.56K
Cash from Financing+	-5.19M	-1.15M	1.95M	7.14M	-5.08M	-7.12M	-3.55M	-2.06M	-7.42M	196.9K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.56M	-1.03M	-27.95K	-383.31K	-85.61K	-1.76M	-2.17M	-2.21M	-3.27M	-1.72M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	3.18M	-1.56M	-2.05M	-1.16M	2.81M	3.3M	5.99M	6.38M	5.64M	-791.9K
FCF Margin %	0.09%	-0.05%	-0.05%	-0.03%	0.08%	0.09%	0.17%	0.15%	0.14%	-0.02%
FCF Growth %	-0.07%	-1.49%	-0.31%	0.43%	3.42%	0.17%	0.81%	0.07%	-0.12%	-1.14%
FCF per Share	0.19	-0.10	-0.13	-0.07	0.18	0.22	0.40	0.44	0.39	-0.06
FCF Conversion (FCF/Net Income)	8.04x	-0.60x	0.07x	-0.45x	-0.86x	-1.62x	-1.81x	-1.52x	-0.97x	0.09x
Interest Paid	-27.43K	21.85K	14.99K	95.97K	0	0	0	523.16K	647.14K	0
Taxes Paid	-52.24K	8.36K	18K	15.44K	0	0	0	3.3K	108.82K	15K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	0.93%	-1.26%	-11.64%	-11.65%	-6.63%	-6.82%	-7.84%	-14.18%	-19.25%	-25.02%
Return on Invested Capital (ROIC)	-2.05%	-2.59%	-8.62%	-14.6%	-15.14%	-11.16%	-15.77%	-12.44%	-21.54%	-17.7%
Gross Margin	85.18%	81.96%	82.09%	81.89%	78.42%	76.89%	75.51%	78.29%	84.66%	82.61%
Net Margin	2.18%	-2.86%	-19.39%	-17.09%	-10.29%	-8.92%	-9.75%	-13.26%	-15.88%	-17.11%
Debt / Equity	0.02x	0.06x	0.15x	0.36x	0.42x	0.41x	0.38x	0.58x	0.63x	0.91x
Interest Coverage	-15.05x	-13.47x	-43.93x	-37.74x	-37.73x	-24.21x	-78.32x	-9.74x	-14.31x	-10.62x
FCF Conversion	8.04x	-0.60x	0.07x	-0.45x	-0.86x	-1.62x	-1.81x	-1.52x	-0.97x	0.09x
Revenue Growth	-9.17%	-1.47%	24.6%	-0.99%	-15.59%	8.88%	-3.89%	16.75%	-5.85%	-4.26%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	-	-	37.51M	36.54M
Product Growth	-	-	-	-	-	-	-	-	-	-2.60%
Manufactured Product, Other	-	-	-	-	-	-	-	-	2.04M	1.33M
Manufactured Product, Other Growth	-	-	-	-	-	-	-	-	-	-34.76%
Kristalose	-	-	11.46M	12.06M	12.9M	15.57M	15.99M	15.21M	-	-
Kristalose Growth	-	-	-	5.24%	6.96%	20.72%	2.74%	-4.93%	-	-
Sancuso	-	-	-	-	-	-	-	13.21M	-	-
Sancuso Growth	-	-	-	-	-	-	-	-	-	-
Product, Vibativ	-	-	-	5.08M	8.69M	10.87M	11.7M	7.49M	-	-
Product, Vibativ Growth	-	-	-	-	71.26%	25.08%	7.66%	-36.03%	-	-
Caldolor	-	-	4.18M	5M	5.22M	5.34M	4.97M	4.83M	-	-
Caldolor Growth	-	-	-	19.71%	4.40%	2.20%	-6.87%	-2.88%	-	-
Acetadote	-	-	6.58M	4.28M	3.82M	1.87M	850.99K	501.04K	-	-
Acetadote Growth	-	-	-	-34.86%	-10.73%	-50.99%	-54.59%	-41.12%	-	-
RediTrex	-	-	-	-	-	856.66K	55.32K	-126.73K	-	-
RediTrex Growth	-	-	-	-	-	-	-93.54%	-329.07%	-	-
Vaprisol	-	-	1.58M	1.76M	936.62K	1.08M	1.86M	-447.7K	-	-
Vaprisol Growth	-	-	-	11.91%	-46.90%	15.01%	72.63%	-124.08%	-	-
Omeclamox-Pak	-	-	1.76M	623.3K	837.83K	257.09K	-388.66K	-	-	-
Omeclamox-Pak Growth	-	-	-	-64.62%	34.42%	-69.31%	-251.18%	-	-	-
Product, Ethyol	-	838.39K	10.84M	10.5M	12.77M	-	-	-	-	-
Product, Ethyol Growth	-	-	1192.37%	-3.09%	21.67%	-	-	-	-	-
Product, Totect	-	-	3.99M	900K	369.91K	-	-	-	-	-
Product, Totect Growth	-	-	-	-77.46%	-58.90%	-	-	-	-	-
Product, Acetadote, Generic	4.5M	4.8M	-	-	-	-	-	-	-	-
Product, Acetadote, Generic Growth	-	6.67%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Non-US	-	-	-	2.1M	1.5M	2.4M	2.2M	1.5M	1.1M	2.7M
Non-US Growth	-	-	-	-	-28.57%	60.00%	-8.33%	-31.82%	-26.67%	145.45%
Outside United States	800K	2M	-	-	-	-	-	-	-	-
Outside United States Growth	-	150.00%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cumberland Pharmaceuticals Inc. (CPIX) reported $41.3M in revenue for fiscal year 2024. This represents a 19% decrease from $51.1M in 2011.

Cumberland Pharmaceuticals Inc. (CPIX) saw revenue decline by 4.3% over the past year.

Cumberland Pharmaceuticals Inc. (CPIX) reported a net loss of $3.3M for fiscal year 2024.

Dividend & Returns

Cumberland Pharmaceuticals Inc. (CPIX) has a return on equity (ROE) of -25.0%. Negative ROE indicates the company is unprofitable.

Cumberland Pharmaceuticals Inc. (CPIX) generated $6.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.